POS0808 DRUG SURVIVAL IN SPONDYLOARTHRITIS: ANTI-IL17 OUTPERFORMS ANTI-TNF IN FIRST BIOLOGIC TREATME...
POS0808 DRUG SURVIVAL IN SPONDYLOARTHRITIS: ANTI-IL17 OUTPERFORMS ANTI-TNF IN FIRST BIOLOGIC TREATMENT
About this item
Full title
Author / Creator
Pham, T. , Curmin, R. , Flachaire, B. , Pinto, S. , Tubach, F. and Miceli Richard, C.
Publisher
Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
Subjects
More information
Scope and Contents
Contents
Background:Objectives:Drug survival rates serve as key indicators for assessing both the efficacy and safety of treatments in real life setting. Our aim was to compare the drug retention of first line biologics, anti-tumor necrosis factor (anti-TNF) therapies or anti-interleukin 17 (anti-IL17) therapies.Methods:This retrospective cohort study, usin...
Alternative Titles
Full title
POS0808 DRUG SURVIVAL IN SPONDYLOARTHRITIS: ANTI-IL17 OUTPERFORMS ANTI-TNF IN FIRST BIOLOGIC TREATMENT
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_3100901487
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3100901487
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2024-eular.4226
